Search
Evans blue
go.drugbank.com/drugs/DB09361InvestigationalCategories: Compounds used in a research, industrial, or household settingParaoxon
go.drugbank.com/drugs/DB13495ExperimentalCategories: Compounds used in a research, industrial, or household settingLecithin
go.drugbank.com/drugs/DB15834InvestigationalA complex mixture of phospholipids, glycolipids, triglycerides, phosphatidylcholines, phosphatidylethanolamines, and phosphatidylinositols.
Mixtures: ONE A DAY TABLETCategories: Compounds used in a research, industrial, or household settingUbiquinone Q2
go.drugbank.com/drugs/DB08690ExperimentalCategories: Compounds used in a research, industrial, or household settingDDP-200
go.drugbank.com/drugs/DB05919ExperimentalDDP200 is developed by Dynogen for the treatment of non-incontinent form of overactive bladder (OAB) with particular focus on both male and female patients with urinary frequency, urinary urgency and nocturia
Delavirdine
go.drugbank.com/drugs/DB00705ApprovedInvestigationalWithdrawnA potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.
Synonyms: (N-[2-[4-[3-(1-methylethylamino)pyridin-2-yl]piperazin-1-yl]carbonyl-1H-indol-5-yl] methanesulfonamide), 2-(4-(5-methanesulfonamido-1H-indol-2-ylcarbonyl)-1-piperazinyl)-N-(1-methylethyl)-3-pyridinamineTRX1
go.drugbank.com/drugs/DB05863ExperimentalTRX1 is being developed for the potential treatment of autoimmune diseases in collaboration with Genentech, Inc. TolerRx is currently conducting a Phase I clinical study of TRX1 in the United Kingdom. … TRX1 is a humanized antibody that binds to the CD4 receptor found on a subset of T cells.
ABX-PTH
go.drugbank.com/drugs/DB05883ExperimentalABX-PTH is a fully human monoclonal antibody generated by Abgenix's technology platform. … This drug targets and neutralizes the action of parathyroid hormone (PTH) for the treatment of a secondary hyperparathyroidism.
Icotinib
go.drugbank.com/drugs/DB11737InvestigationalIcotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc … . was given a “May Proceed” from the US FDA to conduct a Phase I study for the evaluation of icotinib as a treatment of EGFR+ Non-Small Cell Lung Cancer (NSCLC).
Contusugene ladenovec
go.drugbank.com/drugs/DB05322InvestigationalINGN 201(Advexin) is a replication-impaired adenoviral vector that carries the p53 gene, has been evaluated in both preclinical and clinical trials. … Advexin is a well-tolerated and efficacious treatment for numerous cancers, both as monotherapy and in combination with radiation and/or chemotherapy agents.